CD274 and gastric cancer: However, these classifications have not been shown to be useful in clinical practice, and to date only three molecular biomarkers have been shown to predict a response to targeted therapies in GC patients: HER2 positivity for trastuzumab and trastuzumab deruxtecan and MSI and PD-L1 expression for the immune checkpoint.